Publication | Closed Access

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy

UrologyOncologyHormone Analogue TherapyMaximal Androgen BlockadeMedicineBicalutamide Versus FlutamidePharmacotherapyCancer TreatmentProstatic DiseasePharmacologyEndocrine-related Cancer